Phase II study to evaluate primaquine safety and tolerability for radical cure of uncomplicated Plasmodium vivax malaria in children (CHILDPRIM Study)

This clinical trial seeks to fill a global gap in the treatment of uncomplicated vivax malaria: to evaluate the safety and tolerability of short and long-term primaquine treatment regimens for uncomplicated vivax malaria in children. Thus, it hopes to provide a clinical and laboratory description of the main adverse events related to primaquine treatment in children, whether long (14 days) or short (7 days). This will inform safe and tolerable treatment for thousands of children who suffer from successive vivax malaria infections and are cared for by the Brazilian public health service and will help prevent complications after treatment begins.